27
April
Pradaxa Linked To Heart Attack and Bleeding and FDA Undertakes Safety Review
Pradaxa® is oral anticoagulant from the class of the direct thrombin inhibitors. It is being studied for various clinical indications and in some cases it offers an alternative to warfarin as the preferred orally administered anticoagulant (“blood thinner”) since it does not require frequent blood tests for international normalized ratio (INR) monitoring while offering similar results in terms of efficacy. It was developed by Boehringer Ingelheim. http://www.boehringer-ingelheim.com/
Pradaxa® was approved by the FDA in October 2010 for stroke prevention in patients with atrial fibrillation. It is the first of a new crop of blood